A Phase II Trial of Sequential SGN-35 Therapy With Adriamycin, Vinblastine, and Dacarbazine (S-AVD) for Older Patients With Untreated Hodgkin Lymphoma

Trial Profile

A Phase II Trial of Sequential SGN-35 Therapy With Adriamycin, Vinblastine, and Dacarbazine (S-AVD) for Older Patients With Untreated Hodgkin Lymphoma

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 06 Oct 2016

At a glance

  • Drugs Brentuximab vedotin (Primary) ; Dacarbazine; Doxorubicin; Vinblastine
  • Indications Hodgkin's disease
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 27 Sep 2016 Status changed from recruiting to active, no longer recruiting.
    • 17 Jun 2015 Initial results from this study were presented at the 13th International Conference on Malignant Lymphoma, according to a Seattle Genetics media release.
    • 11 Oct 2013 The trial has re-initiated enrolment with an amendment to include monitoring of pancreatic enzymes as well as an exclusion criterion for prior history of pancreatitis according to a Seattle Genetics media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top